Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple blood test may reveal how ewing sarcoma responds to therapy

NCT ID NCT07725783

Knowledge-focused Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This study tests whether changes in a blood protein called ProGRP can signal how well Ewing sarcoma is responding to treatment. Researchers will measure ProGRP levels in 100 newly diagnosed patients before, during, and after chemotherapy, then compare those levels with tumor size on scans. If ProGRP tracks with tumor changes, it could become a non-invasive way to monitor the disease. The blood test results are for research only and will not affect treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If ProGRP levels reliably reflect tumor response, doctors might one day use a simple blood test to monitor Ewing sarcoma treatment, reducing the need for frequent imaging.
What could go wrong
This is an early observational study, not a treatment trial. ProGRP may not correlate well with tumor changes, and results are for research only — they won't guide patient care during the study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of patients aged 10 to 60 years with newly diagnosed, histologically confirmed Ewing sarcoma who are scheduled to initiate first-line systemic therapy at Peking University People's Hospital. Eligible participants must have at least one evaluable lesion on baseline imaging and must not have received prior systemic chemotherapy for Ewing sarcoma or radiotherapy to the primary tumor. Participants will receive chemotherapy and definitive local treatment, including surgery and/or radiotherapy, according to routine clinical practice. Treatment will not be assigned by the study protocol, and serum ProGRP results obtained for research purposes will not be used to guide clinical treatment decisions.

Ages

10 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 10 to 60 years. * Histologically confirmed Ewing sarcoma. * Newly diagnosed disease and scheduled to initiate first-line systemic therapy at Peking University People's Hospital. * No prior systemic chemotherapy for Ewing sarcoma and no prior radiotherapy to the primary tumor. * At least one evaluable lesion on baseline imaging; at least one measurable lesion according to RECIST version 1.1 is required for the primary outcome analysis. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Estimated life expectancy greater than 3 months. * Written informed consent provided by the participant or the participant's legally authorized representative. Exclusion Criteria: * History of another malignant tumor within the previous 3 years, except for an adequately treated malignancy with a negligible risk of recurrence, as determined by the investigator. * New York Heart Association (NYHA) class III or IV heart failure. * Uncontrolled concomitant illness, including uncontrolled diabetes mellitus or an active infection. * Severe infection requiring intravenous antimicrobial treatment within 4 weeks before enrollment. * Clinically significant bleeding or a clear bleeding tendency within 3 months before enrollment. * Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m². * Pregnancy or breastfeeding. * Any condition that, in the investigator's judgment, may compromise participant safety, interfere with study assessments, or prevent compliance with the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ewing sarcoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ewing sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital, Beijing, Beijing 100044

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.